Kulshrestha Satyarth, Barrantes Fidel, Samaniego Milagros, Luan Fu L
Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Clin Transplant. 2014 Sep;28(9):1041-6. doi: 10.1111/ctr.12414.
Chronic opioid usage (COU) is common among patients with end-stage renal disease (ESRD) qualified for kidney transplantation and associated with inferior post-transplant outcomes. The magnitude of COU after kidney transplantation and its impact on transplant outcomes remain unknown. We performed a single-center retrospective study aimed to describe the prevalence of COU during the first year, to identify the predictors of COU and to determine the impact of COU on post-transplant outcomes including the rates of hospitalization and acute rejection during the first year, as well as long-term patient and graft survival. Among 1045 kidney transplant patients, 119 (11.4%) had required continued outpatient prescription of opioid analgesics during the first year after kidney transplantation, mostly for non-surgery-related pain (85%). A positive history of COU prior to transplantation was the strongest predictor of COU in the first year post-transplantation (adjusted odds ratio [AOR] 4.31, p < 0.001). Patients with COU had more often hospital admission during the first year (AOR 2.48, p = 0.001, for 1 or 2 admissions, and AOR 6.03, p < 0.001 for ≥3 admissions), but similar rate of acute rejection (19.3% vs. 15.7%, p = 0.31). During long-term follow-up, however, the patient and/or death-censored kidney survival was not different. COU early post-kidney transplantation, when clinically indicated and properly supervised, does not appear to affect the risk of death and death-censored graft failure.
慢性阿片类药物使用(COU)在符合肾移植条件的终末期肾病(ESRD)患者中很常见,并且与移植后较差的结局相关。肾移植后COU的程度及其对移植结局的影响仍然未知。我们进行了一项单中心回顾性研究,旨在描述第一年COU的患病率,确定COU的预测因素,并确定COU对移植后结局的影响,包括第一年的住院率和急性排斥反应率,以及患者和移植物的长期存活率。在1045例肾移植患者中,119例(11.4%)在肾移植后的第一年需要持续门诊开具阿片类镇痛药,主要用于非手术相关疼痛(85%)。移植前有COU阳性史是移植后第一年COU最强的预测因素(调整后的优势比[AOR]为4.31,p<0.001)。COU患者在第一年更常住院(1次或2次住院的AOR为2.48,p = 0.001,≥3次住院的AOR为6.03,p<0.001),但急性排斥反应率相似(19.3%对15.7%,p = 0.31)。然而,在长期随访中,患者和/或死亡审查的肾脏存活率没有差异。肾移植后早期的COU,在有临床指征且得到适当监督的情况下,似乎不会影响死亡风险和死亡审查的移植物失败风险。